2003 - The Year of BBG

The only reason to hold BBG is the possibility of a decent merger, which remains a significant gamble imo.

My first choice for 2003 is Alizyme (AZM) (currently 34.5p) on the basis of news flow expected during the coming twelve months (including licensing deals), the low risk nature of its pipeline, the confidence conferred by recent director share purchases, and the potential for a take-over bid. I estimate current fair value to be around £2 per share, rising to £4 during 2003 if all goes well.